logo
  

Lilly To Present Phase 3 Data For Ixekizumab In Psoriasis & Psoriatic Arthritis

Eli Lilly and Co. (LLY) said that it will showcase results from pivotal Phase 3 data investigating ixekizumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 74th annual meeting of the American Academy of Dermatology or AAD, which will take place March 4-8, 2016, in Washington, D.C.

A total of 29 abstracts, including three oral presentations, will feature Lilly's ixekizumab data for the treatment of moderate-to-severe plaque psoriasis across a number of areas, including efficacy and safety data at 12 weeks and 60 weeks, patient-reported outcomes and data evaluating the efficacy and safety of ixekizumab compared to etanercept. Two abstracts evaluating the efficacy and safety of ixekizumab for the treatment of active psoriatic arthritis will also be presented.

Ixekizumab is an IgG4 monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of pro-inflammatory cytokines and chemokines.

Psoriasis is a chronic, immune disease that affects the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects approximately 125 million people worldwide, approximately 20 percent of whom have moderate-to-severe plaque psoriasis. Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease. The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT